Literature DB >> 2191992

Steroid dose sparing: pharmacodynamic responses to single versus divided doses of methylprednisolone in man.

W G Reiss1, R L Slaughter, E A Ludwig, E Middleton, W J Jusko.   

Abstract

Inhibitory drug interactions affecting the metabolism of methylprednisolone (MP) may produce either steroid sparing or adverse effects partly by increasing the exposure time to the steroid. This phenomenon can be mimicked by administering MP in divided doses. Two types of responses were compared after a single MP dose (40 mg bolus) and a divided regimen (20 mg bolus and a 5 mg bolus 8 hours later) in six healthy male volunteers. The suppression of basophils measured as whole blood histamine and plasma cortisol concentrations was assessed during 32 hours. The 37.5% reduction in dose produced a 23% overall decreased blood histamine response. A pharmacodynamic model for basophil cell distribution to and from an extravascular compartment describes the effects of MP after both regimens. A slower initial decline in blood histamine after the divided regimen may be related to incomplete suppression of basophil cell return to blood. The 50% inhibitory concentrations of MP of about 5 ng/ml were similar for both regimens. The decline and return of cortisol concentrations were similar between MP treatments with suppression continuing for 24 hours. The 50% inhibitory concentrations of MP values for adrenal suppression were about 1 ng/ml. Pharmacodynamic modeling is useful in quantitating corticosteroid responses and generally predicted the "dose-sparing" effects that were achieved by prolonging MP plasma concentrations. This study supports previous clinical observations that patients may require morning through evening exposure to MP to optimize efficacy while adrenal suppression is being minimized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2191992     DOI: 10.1016/0091-6749(90)90051-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

1.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

2.  Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone.

Authors:  F S Chow; A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 3.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

4.  Pharmacodynamic modeling of cortisol suppression from fluocortolone.

Authors:  K H Lew; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.

Authors:  J A Wald; D E Salazar; H Y Chen; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

7.  Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.

Authors:  K H Lew; E A Ludwig; M A Milad; K Donovan; E Middleton; J J Ferry; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

8.  Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants.

Authors:  Sebastian Oliver Decker; Frieder Keller; Jens Mayer; Sylvia Stracke
Journal:  Med Klin (Munich)       Date:  2009-06-16

9.  Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.

Authors:  L E Fisher; E A Ludwig; J A Wald; R R Sloan; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.